Related Experiment Video
Updated: Jul 5, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Characteristics of an ideal rotavirus vaccine
Keith S Reisinger1, Stan L Block
1Primary Physicians Research, Pittsburgh, Pennsylvania 15241, USA. KSRPPR@aol.com
Insights
New rotavirus vaccines significantly reduce childhood diarrhea hospitalizations. These vaccines, RotaTeq and Rotarix, are highly effective and safe for infants, lowering healthcare costs.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Diseases
Background:
- Rotavirus gastroenteritis is a leading cause of severe diarrhea and hospitalization in children globally.
- The high disease burden necessitates effective prevention strategies, particularly vaccination.
Purpose of the Study:
- To evaluate the efficacy and safety of two new rotavirus vaccines.
- To assess the impact of rotavirus vaccination on public health and healthcare resource utilization.
Main Methods:
- Clinical trials involving over 60,000 infants for each vaccine (RotaTeq and Rotarix).
- Phase 3 clinical trials were conducted to assess vaccine performance.
- Safety assessments included monitoring for intussusception risk.
Main Results:
- Both RotaTeq and Rotarix demonstrated high efficacy in preventing rotavirus gastroenteritis.
- Vaccines were well-tolerated with no increased risk of intussusception.
- Significant reductions in rotavirus-associated morbidity, mortality, and healthcare utilization are anticipated.
Conclusions:
- Rotavirus vaccines represent a major advancement in pediatric infectious disease prevention.
- Widespread vaccination is expected to substantially decrease the global burden of rotavirus disease.
- These vaccines offer a safe and effective tool to reduce childhood hospitalizations and healthcare costs.
Abstract:
Rotavirus gastroenteritis primarily affects children younger than 5 years of age and is the leading cause of diarrhea-related hospitalizations worldwide. The substantial morbidity associated with this disease and the major burden on healthcare resources underscore the need for an effective vaccine. Two recently developed vaccines (RotaTeq [rotavirus vaccine, live, oral, pentavalent], and Rotarix [rotavirus vaccine, live]) share some characteristics of an ideal rotavirus vaccine. High efficacy, excellent tolerability, and no increased risk of intussusception were shown in separate clinical trials of more than 60,000 infants for each trial, as well as in smaller phase 3 clinical trials of each vaccine. Vaccination against rotavirus will substantially reduce rotavirus gastroenteritis-associated morbidity and mortality and, in so doing, bring about a significant reduction in rotavirus gastroenteritis-associated healthcare utilization.
Related Concept Videos
Poliomyelitis
Respiratory Syncytial Virus Disease
